Table of Contents Table of Contents
Previous Page  689 / 812 Next Page
Information
Show Menu
Previous Page 689 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S685

EV1050

Interferon-induced psychosis: Myth

or reality?

A. Antunes

, L. Sousa

Hospital de Santa Maria, Lisbon Academic Medical Center, Psychiatry

and Mental Health, Lisbon, Portugal

Corresponding author.

Introduction

Interferon combined with ribavirin is widely used

to decrease the burden of Hepatitis C virus (HCV), but some serious

side effects might limit its usefulness. There has been recently a

growing awareness about neuropsychiatric complications of many

drug treatments. Anecdotal case reports of HCV treatment induced

psychosiswere published but there seems to be no consensus about

the causative relation and no systematic reviews were done to the

date.

Objective

To describe a paradigmatic case that was managed as

an iatrogenic psychotic episode following interferon associated

with ribavirin.

Aim

Call attention to problems that interfere with the recogni-

tion, diagnosis and management of drugs induced psychosis.

Methods

Bibliographic research was conducted through the

PubMed in the Medline library and clinical information was

obtained through medical records and clinical interviews with the

patient.

Results

A 50-year-old Brazilian woman, with a previous episode

of postpartum depression, presented with paranoid psychosis six

months after initiating HCV antiviral therapy. Psychotic symptoms

consisted of persecutory delusions and auditory hallucinations and

developed together with agitation and aggressive behavior. Psy-

chiatric hospitalization was required and psychosis resolved with

discontinuation of therapy and initiation of risperidone. Laboratory

tests and brain imageswere of no help in the etiologic investigation.

Conclusions

There are many drugs known to possibly cause neu-

ropsychiatric symptoms. It is the job of every physician to be aware

of this hypothesis especially in cases with acute onset and atypical

presentations.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2035

EV1051

Use of cannabis components in the

treatment of mental disorders

C. Tsopelas

, M. Dimitraka , P. Ntounas , A. Gatos-Gatopoulos ,

D. Karadima , T. Charalampos

Psychiatric Hospital of Attica, 5th Dept of Acute Admissions, Athens,

Greece

Corresponding author.

Introduction

There is evidence that supports the increased risk

of developing psychosis or psychotic like symptoms in vulnera-

ble populations after use of cannabis. Cannabis’ main psychoactive

component,

9-tetrahydrocannabinol (THC), induces acute psy-

chotic effects and cognitive impairment. But there is also evidence

to suggest that molecules in the cannabis plant could have an

antipsychotic affect.

Aims

In this review we are trying to explore the possibilities of

cannabis use as a therapeutic agent in mental disorders.

Methods

Thorough research of the main databases, and web

search engines for relevant studies, using appropriate keywords.

We scrutinize them independently, before reaching consensus

about appropriateness.

Results

In animal models repeated treatment with cannabis con-

stituent cannabidiol CBD or the atypical antipsychotic clozapine

attenuates or reverses the schizophrenia-like behavioral disrup-

tion.

In humans there are data that CBD counteracts psychotic symp-

toms and cognitive impairment associated with cannabis use. Also

CBD may lower the risk for developing cannabis use associated

psychosis. There are opposite effects of CBD and THC on brain activ-

ity patterns in key regions implicated in the pathophysiology of

schizophrenia, such as the striatum, hippocampus and prefrontal

cortex.

Conclusions

The possible mechanism of action of GBD is not fully

clarified, as it may involve anti-inflammatory or neuroprotective

properties. These initial clinical studies with CBD treatment of psy-

chotic symptoms argument the potential of CBD as an effective

antipsychotic compound. Mechanisms responsible for these effects

need to be further investigated.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2036

EV1052

Nicotine as therapeutic agent in

treatment of mood disorders

C. Tsopelas

, N. Petros , D. Maria , P. Dimitris , G.G. Angelica ,

K. Dimitra , T. Charalampos

Psychiatric Hospital of Attica, 5th Department of Acute Admissions,

Athens, Greece

Corresponding author.

Introduction

The plant that has as active ingredient nicotine was

chewed or smoked for many years from American natives, for its

therapeutic properties. Nowadays after the extensive negative atti-

tude towards smoking, the main provider of nicotine, researchers

are now pointing out the therapeutic possibilities of nicotine in

mood disorders, as a substance that is acting in the acetylcholine

receptors in the brain.

Aims

In this review we are trying to explore the possibilities of

nicotine use as a therapeutic agent.

Methods

We did a detailed research of the main medical

databases, and web search engines for relevant studies. We

scrutinize them independently, before reaching consensus about

appropriateness for inclusion in the study.

Results

Diadermal administration of nicotine has a positive effect

in depressive disorder in 3–8 days, an effect that in one study

was reversed after cessation of nicotine. Patients with depres-

sion and/or healthy subjects show improvement of attention and

working memory after diadermal use of nicotine. Research is not

conclusive in the sustainability of these positive affects as other

researchers emphasize their short effect in mood.

Conclusion

Nicotine presents as part of novel and promising

therapeutic agents with complex interactions with other neuro-

transmitters in the brain. Before condemning nicotine along with

smoking we should acknowledge the potential use of nicotine as

a therapeutic compound since research shows that some of these

positive effects appear not only to smokers after abstinence but also

to non-smokers.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2037

EV1053

Awkward movements:

Extrapyramidal symptoms in a group

of patients treated with aripiprazole

long acting injectable

C. Victor

1 ,

, S. Berta

1

, T. Ivan

2

, O. Silvia

3

, C. Sandra

3

,

M. Estanislao

3

, M. Luis Miguel

3

, J. Moreno

1

1

Parc de Salut Mar, INAD, Hospital del Mar, Barcelona, Spain

2

Parc de Salut Mar, INAD, Barcelona, Spain